: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy.
This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects. 125459
: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations. : Characterizing potential immune responses to the viral
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA. Guide to EMA Guideline 125459 : Checking if
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .
The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459
: Checking if the patient might "shed" or spread the virus/vector through secretions.